Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SANGUINE CORP. (SGNC) -- Ignore unavailable to you. Want to Upgrade?

To: Dixie7777 who wrote (2525)	7/4/1998 6:37:00 PM
From: KIPPer	Read Replies (2) \| Respond to of 5402

Dixie, I second what you are asking for valuation from our Valuation Leader Mr. Forthright. Before we embark on SGNC's valuation let's apply an experimental model to a stock that has already finished or at least applied for the first stage of clinical trials(have they?)Moreover, Entremed did gain national attention recently with their announcement in NY times and the subsequent explosion in stock price. IMO this would be the way to start. Once we have Mr.Forthrights Entremed valuation in place we could easily apply it to SGNC. And since EVERYONE AGREES THAT MR. FORTHRIGHT IS THE VALUATION LEADER among us, let us follow his lead. Mr. Forthright we are looking to your valuable VALUATION model on Entremed. thanks in advance KIP